Form 4: Schrodinger Executive Abel Receives Stock Options and Restricted Stock Units

Robert Lorne Abel, EVP and Chief Scientific Officer at Schrodinger, Inc., reports the acquisition of stock options and restricted stock units.

Summary

• Robert Lorne Abel, an executive at Schrodinger, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, Abel was granted 12,500 restricted stock units (RSUs) and an option to purchase 50,000 shares of common stock at an exercise price of $21.24.
• The RSUs vest in equal installments annually from March 4, 2026, to March 4, 2029, contingent upon continued service.
• The stock options vest 25% on March 3, 2026, with the remainder vesting in equal monthly installments through March 3, 2029.
• Following these transactions, Abel beneficially owns 20,615 shares of common stock, including 17,773 unvested RSUs, and options to purchase 50,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of RSUs and stock options aligns Abel's interests with those of the company and its shareholders.
• The vesting schedules incentivize continued service and contribution to Schrodinger's success.

Future Outlook

The vesting schedules for the RSUs and stock options extend through 2029, indicating a long-term incentive structure.

Industry Context

Stock option and RSU grants are common practices in the biotech and pharmaceutical industries to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Companies like Relay Therapeutics, Recursion Pharmaceuticals, and Exscientia also utilize stock options and RSU grants as part of their executive compensation packages.
• The vesting schedules and grant sizes are generally comparable to industry standards for similar roles and company sizes.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning executive interests with company performance.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates